TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET 30
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 32
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 CURRENCY AND PRICING 38
2.5 DBMR TRIPOD DATA VALIDATION MODEL 39
2.6 MULTIVARIATE MODELLING 42
2.7 PRODUCT TYPE LIFELINE CURVE 42
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.9 DBMR MARKET POSITION GRID 44
2.10 MARKET APPLICATION COVERAGE GRID 45
2.11 VENDOR SHARE ANALYSIS 46
2.12 SECONDARY SOURCES 47
2.13 ASSUMPTIONS 47
3 EXECUTIVE SUMMARY 48
4 PREMIUM INSIGHTS 50
4.1 PESTEL ANALYSIS 51
4.2 PORTER'S FIVE FORCES MODEL 52
5 MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET: REGULATIONS 53
6 MARKET OVERVIEW, MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET 55
6.1 DRIVERS 57
6.1.1 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH CONTENT SCREENING 57
6.1.2 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 57
6.1.3 INCREASING RESEARCH ACTIVITIES ASSOCIATED WITH THE USAGE OF HIGH CONTENT SCREENING 58
6.1.4 INCREASING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 59
6.2 RESTRAINTS 59
6.2.1 HIGH COST ASSOCIATED WITH INITIAL SETUP AND MAINTENANCE 59
6.2.2 COMPLEXITY ASSOCIATED WITH CELLULAR AND MOLECULAR SAMPLES 60
6.3 OPPORTUNITIES 61
6.3.1 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS) PROVIDING HCS SERVICES 61
6.3.2 RISING INTEGRATION WITH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT 61
6.3.3 INCREASING GOVERNMENT INITIATIVE AND FUNDING IN R&D 62
6.4 CHALLENGES 62
6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE HCS 62
6.4.2 DATA SECURITY AND DATA MANAGEMENT PROBLEMS IN HCS 63
7 MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE 64
7.1 OVERVIEW 65
7.2 INSTRUMENTS 68
7.2.1 CELL IMAGING AND ANALYSIS SYSTEM 69
7.2.1.1 FIXED 69
7.2.1.2 MOBILE 69
7.2.2 HIGH-CONTENT AND SCREENING SYSTEM 69
7.2.2.1 FIXED 70
7.2.2.2 MOBILE 70
7.2.3 FLOW CYTOMETRY 70
7.2.4 INVITROGEN HCA ONSTAGE INCUBATOR 70
7.2.5 MICROPLATE MOVER 70
7.2.6 OTHERS 70
7.3 SOFTWARE 70
7.4 CONSUMABLES 71
7.4.1 REAGENTS & ASSAY KITS 72
7.4.2 MICROPLATES 72
7.4.3 OTHERS 72
7.5 ACCESSORIES 72
7.6 SERVICES 73
8 MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET, BY APPLICATION 75
8.1 OVERVIEW 76
8.2 PRIMARY AND SECONDARY SCREENING 79
8.2.1 INSTRUMENTS 80
8.2.2 CONSUMABLES 80
8.2.3 ACCESSORIES 80
8.2.4 SERVICES 80
8.3 TARGET IDENTIFICATION AND VALIDATION 80
8.3.1 INSTRUMENTS 81
8.3.2 CONSUMABLES 81
8.3.3 ACCESSORIES 81
8.3.4 SERVICES 82
8.4 TOXICITY STUDIES 82
8.4.1 INSTRUMENTS 83
8.4.2 CONSUMABLES 83
8.4.3 ACCESSORIES 83
8.4.4 SERVICES 83
8.5 COMPOUND PROFILING 83
8.5.1 INSTRUMENTS 84
8.5.2 CONSUMABLES 84
8.5.3 ACCESSORIES 84
8.5.4 SERVICES 85
8.6 OTHER APPLICATIONS 85
9 MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY 86
9.1 OVERVIEW 87
9.2 MICROSCOPY 90
9.3 FLOW CYTOMETRY 90
9.4 IMMUNOHISTOCHEMISTRY 91
9.5 MASS SPECTROMETRY 92
9.6 ELISA 93
9.7 WESTERN BLOTTING 94
9.8 OTHERS 94
9.8.1 3D CELL CULTURE MODEL 95
9.8.1.1 STEROIDS 96
9.8.1.2 ORGANOIDS 96
9.8.1.3 TISSUE ON A CHIP 96
9.8.2 EXTRACELLULAR MATRIX BASED SCAFFOLD 96
9.8.3 SYNTHETIC HYDROGEL AND SCAFFOLD 96
10 MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET, BY END USER 97
10.1 OVERVIEW 98
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 101
10.2.1 INSTRUMENTS 101
10.2.2 CONSUMABLES 102
10.2.3 ACCESSORIES 102
10.2.4 SERVICES 102
10.3 CONTRACT RESEARCH ORGANIZATIONS 102
10.3.1 INSTRUMENTS 103
10.3.2 CONSUMABLES 103
10.3.3 ACCESSORIES 103
10.3.4 SERVICES 103
10.4 LABORATORIES 104
10.4.1 INSTRUMENTS 105
10.4.2 CONSUMABLES 105
10.4.3 ACCESSORIES 105
10.4.4 SERVICES 105
10.5 ACADEMIC AND GOVERNMENT INSTITUTES 105
10.5.1 INSTRUMENTS 106
10.5.2 CONSUMABLES 106
10.5.3 ACCESSORIES 106
10.5.4 SERVICES 106
10.6 OTHERS 107
11 MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL 108
11.1 OVERVIEW 109
11.2 DIRECT TENDERS 112
11.3 RETAIL SALES 112
12 MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET, BY REGION 114
12.1 MIDDLE EAST AND AFRICA 115
12.1.1 SOUTH AFRICA 126
12.1.2 SAUDI ARABIA 133
12.1.3 BAHRAIN 140
12.1.4 U.A.E 147
12.1.5 KUWAIT 154
12.1.6 OMAN 161
12.1.7 QATAR 168
12.1.8 EGYPT 175
12.1.9 ISRAEL 182
12.1.10 REST OF MIDDLE EAST AND AFRICA 189
13 MIDDLE EAST & AFRICA HIGH CONTENT SCREENING MARKET, COMPANY LANDSCAPE 190
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 190
14 MIDDLE EAST & AFRICA CONTENT SCREENING MARKET, COMPANY PROFILES 191
14.1 THERMO FISHER SCIENTIFIC INC. (2022) 191
14.1.1 COMPANY SNAPSHOT 191
14.1.2 REVENUE ANALYSIS 191
14.1.3 COMPANY SHARE ANALYSIS 192
14.1.4 PRODUCT PORTFOLIO 192
14.1.5 RECENT DEVELOPMENT 192
14.2 BD 193
14.2.1 COMPANY SNAPSHOT 193
14.2.2 REVENUE ANALYSIS 193
14.2.3 COMPANY SHARE ANALYSIS 194
14.2.4 PRODUCT PORTFOLIO 194
14.2.5 RECENT DEVELOPMENTS 194
14.3 PERKINELMER INC. (2022) 195
14.3.1 COMPANY SNAPSHOT 195
14.3.2 REVENUE ANALYSIS 195
14.3.3 COMPANY SHARE ANALYSIS 196
14.3.4 PRODUCT PORTFOLIO 196
14.3.5 RECENT DEVELOPMENTS 197
14.4 YOKOGAWA ELECTRIC CORPORATION (2022) 198
14.4.1 COMPANY SNAPSHOT 198
14.4.2 REVENUE ANALYSIS 198
14.4.3 COMPANY SHARE ANALYSIS 199
14.4.4 PRODUCT PORTFOLIO 199
14.4.5 RECENT DEVELOPMENT 199
14.5 MOLECULAR DEVICES, LLC. (A SUBSIDIARY OF DANAHER CORPORATION) 200
14.5.1 COMPANY SNAPSHOT 200
14.5.2 REVENUE ANALYSIS 200
14.5.3 COMPANY SHARE ANALYSIS 201
14.5.4 PRODUCT PORTFOLIO 201
14.5.5 RECENT DEVELOPMENT 202
14.6 AGILENT TECHNOLOGIES, INC. (2022) 203
14.6.1 COMPANY SNAPSHOT 203
14.6.2 REVENUE ANALYSIS 203
14.6.3 PRODUCT PORTFOLIO 204
14.6.4 RECENT DEVELOPMENT 204
14.7 ALIGNED GENETICS, INC. (2022) 205
14.7.1 COMPANY SNAPSHOT 205
14.7.2 REVENUE ANALYSIS 205
14.7.3 PRODUCT PORTFOLIO 206
14.7.4 RECENT DEVELOPMENT 206
14.8 ARACELI BIOSCIENCES 207
14.8.1 COMPANY SNAPSHOT 207
14.8.2 PRODUCT PORTFOLIO 207
14.8.3 RECENT DEVELOPMENT 207
14.9 AXXAM S.P.A 208
14.9.1 COMPANY SNAPSHOT 208
14.9.2 PRODUCT PORTFOLIO 208
14.9.3 RECENT DEVELOPMENT 208
14.10 BIO-RAD LABORATORIES, INC. (2022) 209
14.10.1 COMPANY SNAPSHOT 209
14.10.2 REVENUE ANALYSIS 209
14.10.3 PRODUCT PORTFOLIO 210
14.10.4 RECENT DEVELOPMENTS 210
14.11 CARL ZEISS AG 211
14.11.1 COMPANY SNAPSHOT 211
14.11.2 REVENUE ANALYSIS 211
14.11.3 PRODUCT PORTFOLIO 212
14.11.4 RECENT DEVELOPMENT 212
14.12 CORNING INCORPORATED 213
14.12.1 COMPANY SNAPSHOT 213
14.12.2 REVENUE ANALYSIS 213
14.12.3 PRODUCT PORTFOLIO 214
14.12.4 RECENT DEVELOPMENT 214
14.13 DE NOVO SOFTWARE 215
14.13.1 COMPANY SNAPSHOT 215
14.13.2 PRODUCT PORTFOLIO 215
14.13.3 RECENT DEVELOPMENTS 215
14.14 EVIDENT 216
14.14.1 COMPANY SNAPSHOT 216
14.14.2 PRODUCT PORTFOLIO 216
14.14.3 RECENT DEVELOPMENT 216
14.15 GENEDATA AG 217
14.15.1 COMPANY SNAPSHOT 217
14.15.2 PRODUCT PORTFOLIO 217
14.15.3 RECENT DEVELOPMENT 217
14.16 MERCK KGAA 218
14.16.1 COMPANY SNAPSHOT 218
14.16.2 REVENUE ANALYSIS 218
14.16.3 PRODUCT PORTFOLIO 219
14.16.4 RECENT DEVELOPMENTS 219
14.17 MILTENYI BIOTEC 220
14.17.1 COMPANY SNAPSHOT 220
14.17.2 PRODUCT PORTFOLIO 220
14.17.3 RECENT DEVELOPMENT 221
14.18 SARTORIUS AG 222
14.18.1 COMPANY SNAPSHOT 222
14.18.2 REVENUE ANALYSIS 222
14.18.3 PRODUCT PORTFOLIO 223
14.18.4 RECENT DEVELOPMENTS 223
14.19 SYSMEX CORPORATION 224
14.19.1 COMPANY SNAPSHOT 224
14.19.2 REVENUE ANALYSIS 224
14.19.3 PRODUCT PORTFOLIO 225
14.19.4 RECENT DEVELOPMENT 225
14.20 ZIFO RND SOLUTIONS 226
14.20.1 COMPANY SNAPSHOT 226
14.20.2 PRODUCT PORTFOLIO 226
14.20.3 RECENT DEVELOPMENTS 226
15 QUESTIONNAIRE 227
16 RELATED REPORTS 231

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.